DAFTAR PUSTAKA

1. Espinoza LR. Buerger's disease: thromboangiitis obliterans 100 years after the initial description. Am J Med Sci. Apr 2009;337(4):285-6. 2. Malecki R, Zdrojowy K, Adamiec R. Thromboangiitis obliterans in the 21st century-A new face of disease.Atherosclerosis. Feb 12 2009 3. Gregory Piazza, Mark A.Creager. Thromboangiitis Obliterans. American Heart Association. Circulation. 2010;121:1858-61. 4. Ozanan R Meireles, Vincent Loprz Rowe, E Jerry Cohn, Fransisco Talavera. Buergers Disease (Thromboangiitis Obliterans). Emedicine. 2012. 5. Salimi J, Tavakkoli H, Salimzadeh A, Ghadimi H, Habibi G, Masoumi AA. Clinical characteristics of Buerger's disease in Iran. J Coll Physicians Surg Pak. Aug 2008;18(8):502-5. 6. Iwai T, Inoue Y, Umeda M, Huang Y, Kurihara N, Koike M, Ishikawa I. Oral bacteria in the occluded arteries of patients with Buerger disease. J Vasc Surg. 2005;42:107-15. 7. Eichhorn J, Sima D, Lindschau C, Turowski A, Schmidt H, Schneider, et al. Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci. 1998;315:17-23. 8. Avcu F, Akar E, Demirkilic U, Yilmaz E, Akar N, Yalcin A. The role of prothrombotic mutations in patients with Buergers disease. Thromb Res. 2000;100:143-7. 9. Maslowski L, McBane R, Alexewics P, Wysokinski WE, Antiphospolipid antibodies in thromboangiitis obliterans. Vasc Med. 2002;7:259-64. 10. Bozkurt AK, Koksal C, Ercan M. The altered hemorheologic parameters in thromboangiitis oliterans: a new insight. Clin Appl Thromb Hemost. 2004;10:45-50. 11. Y. Shoenfeld, Richard Cervera, Eric Gershwin. Diagnostic Criteria in Autoimmune Disease. Buergers Disease. Humana Press, Totowa, NJ. 2008 12. Puechal X, Fiessinger J N, Kahan A. Rheumatic manifestations in patients with thromboangiitis obliterans (Buerger disease). J Rheumatol 1999;26:1764-8. 13. Perttu ER Arkkila. Thromboangiitis obliterans (Buergers disease). Journal of Rare Diseases. 2006;1:14

14. Motukuru V, Suresh KR, Vivekanand V, Raj S, Girija KR. Therapeutic angiogenesis in Buerger's disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells. J Vasc Surg. Dec 2008;48(6 Suppl):53S-60S; discussion 60S. 15. Kulkarni S, Kulkarni G, Shyam AK, Kulkarni M, Kulkarni R, Kulkarni V. Management of thromboangiitis obliterans using distraction osteogenesis: A retrospective study. Indian J Orthop. Sep 2011;45(5):459-64. 16. Mills JL Sr. Buerger Disease in the 21st century: diagnosis, clinical features, and therapy. Semin Vasc Surg 2003;16:179-89. 17. Olin JW, Young JR, Graor RA. The changing clinical spectrum of thromboangiitis obliterans (Buerger disease). Circulation 1990;82 (Suppl. IV): IV3-8. 18. Puechal C, Fiessinger JN. Thromboangiitis obliterans or Buerger disease: challenges for the rheumatologist. Rheumatology 2007;46:192-9. 19. Papa MZ, Adar R. A Critical look at thromboangiitis obliterans (Buerger disease). Vac Surg. 1992;5:1-21. 20. Papa MZ, Rabi I, Adar R. A point scoring system for the clinical diagnosis of Buerger disease. Eur J Vasc Endo Vasc Surg. 1996;11:335-9. 21. Olin JW. Thromboangiitis obliterans (Buerger disease). In: Rutherford R.B, (ed.) Rutherfords Vascular Surgery. 6th ed. Philadelphia: Elsevier-Saunders, 2005: 404-19. 22. Cooper LT, Henderson SS, Ballman KV, Offord KP, Tse TS, Holmes DR, et al. A prospectice, case-control study of tobacco dependence in thromboangiitis obliterans (Buerger disease). Angiology 2006;57:73-8. 23. Lawrence PF, Lund OI, Jimenez JC, Muttalib R. Substitution of smokeless tobacco for cigarettes in Buerger's disease does not prevent limb loss. J Vasc Surg. Jul 2008;48(1):2102. 24. Tavakoli H, Salimi J, Rashidi A. Reply: "Treatment-of-choice for Buerger's disease (thromboangiitis obliterans): still an unresolved issue". Clin Rheumatol. Jun 2008;27(6):813. 25. Miyamoto K, Nishigami K, Nagaya N, Akutsu K, Chiku M, Kamci M, et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation. 2006;114:2769-84.